| 4.45 -0.2 (-4.3%) | 12-11 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 6.95 | 1-year : | 8.72 |
| Resists | First : | 5.95 | Second : | 7.46 |
| Pivot price | 4.99  |
|||
| Supports | First : | 3.5 | Second : | 2.91 |
| MAs | MA(5) : | 4.72 |
MA(20) : | 4.77 |
| MA(100) : | 9.22 |
MA(250) : | 24.29 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 28.8 |
D(3) : | 31.6 |
| RSI | RSI(14): 41.3 |
|||
| 52-week | High : | 81.02 | Low : | 3.5 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ BDRX ] has closed above bottom band by 28.8%. Bollinger Bands are 49.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 4.94 - 4.98 | 4.98 - 5.01 |
| Low: | 4.24 - 4.28 | 4.28 - 4.3 |
| Close: | 4.4 - 4.46 | 4.46 - 4.5 |
Biodexa Pharmaceuticals Plc, a drug delivery technology company, focuses on the bio-delivery and biodistribution of medicines in Belgium and internationally. The company is developing MTX110, a direct delivery treatment for diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme; MTD211, a long-acting formulation of brexpiprazole for the treatment of schizophrenia and adjunctive treatment of major depressive disorder; and MTX223, a long-acting injectable formulations of biologic products, such as mAbs or other high molecular weight proteins. It also offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.
Fri, 22 Nov 2024
Biodexa Pharmaceuticals Shareholders Approve Key Share Value Resolutions | BDRX Stock News - StockTitan
Fri, 22 Nov 2024
Result of General Meeting - GlobeNewswire
Thu, 21 Nov 2024
Biodexa's eRapa Shows 29% Polyp Reduction in FAP Trial, Advances Cancer & Diabetes Pipeline | BDRX Stock News - StockTitan
Mon, 18 Nov 2024
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biodexa Pharmaceuticals Plc - BDRX - PR Newswire
Tue, 12 Nov 2024
Biodexa Pharmaceuticals Regains Nasdaq Compliance, Averts Delisting Risk | BDRX Stock News - StockTitan
Tue, 12 Nov 2024
Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Regains Compliance For Continued Listing on Nasdaq - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 2.45e+009 (%) |
| Held by Institutions | 10.1 (%) |
| Shares Short | 28 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -6.44e+006 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -7 % |
| Return on Assets (ttm) | 931.3 % |
| Return on Equity (ttm) | -37.6 % |
| Qtrly Rev. Growth | 83000 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -67.53 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -76.6 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -8 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.07 |
| Price to Cash Flow | 0.26 |
| Dividend | 0 |
| Forward Dividend | 16000 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|